Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It

For a long time, the equation was simple: more reps in the field meant more interactions with clinicians which would lead to higher prescription volumes. That’s changed a lot in recent years. Today, the sheer number of people on a roster doesn’t give you the full picture of your commercial impact. We often see that up to 30% of a field sales team’s capacity is underperforming at any given time, even when every territory technically has a representative assigned to it.

The reality is that a "filled seat" does not equal full productivity. Disengagement, misalignment with modern HCP preferences, and the inherent learning curves of the job mean that the headcount metric is creating a false sense of security for pharma leaders. If you are solely looking at vacancy rates, you’re likely missing the invisible revenue leaks happening right under your nose.

PE: How do under-covered territories or sudden vacancies disrupt HCP relationships and the overall promotional cadence?
Pinto: HCPs today are stretched incredibly thin. They rely on pharmaceutical reps not just for product drops, but for clinical education, patient support resources, and continuity of care.

When a territory is vacant or managed by someone who is under-performing, that vital relationship is immediately disrupted. Call plans fall apart. Promotional momentum stalls. And HCPs quickly shift their attention to a competitor who is simply showing up consistently at their office.

It takes months, and sometimes years, to build deep trust with a high-decile prescriber. A sudden vacancy doesn't just mean a temporary pause in sales. Instead, it erodes that trust. When a new rep finally steps in, they aren't just starting from zero, they more often than not are starting from a deficit and must rebuild the reliability that the previous gap destroyed.

PE: From an operational standpoint, what is the reality of managing coverage gaps during turnover, extended leaves, or ramp-up periods?
Pinto: The operational burden of managing these gaps is huge. Plus, it’s a quiet drain on a brand's bottom line. When a rep leaves, or goes on extended leave like FMLA, the territory doesn't just sit on pause. Neighboring reps are often asked to stretch themselves thin to cover the gap, which dilutes their effectiveness in their own primary regions.

But that’s not the only challenge. The ramp-up time for a new hire is incredibly costly. It typically takes a new representative three to six months to truly understand the science, master the territory routing, and establish meaningful HCP rapport. During this transition period, the territory is technically "staffed" on HR's spreadsheet, but from a revenue and engagement standpoint, it is operating at a fraction of its true potential.

PE: Knowing these pitfalls, how are leading pharmaceutical organizations redesigning their field models to solve this issue?
Pinto: The smartest commercial leaders are shifting their mindset away from "hiring speed" and moving toward "continuous territory coverage." They recognize that turnover and leaves of absence are inevitable realities, not unexpected emergencies. Instead of scrambling to fill a vacancy when someone resigns, they are building resilient deployment models that are designed to absorb instability without dropping the ball on HCP engagement.

This means moving away from rigid, legacy structures and embracing agile deployment strategies. Leading organizations are partnering with teams that can rapidly deploy flexible, highly trained resources the moment a gap is identified, ensuring that the brand’s voice is never absent from a key market.

PE: We are hearing a lot about hybrid field teams. How are virtual and in-person combinations being used to maintain momentum and protect revenue during these transition periods?
Pinto:Hybrid teams serve as both a safety net and a growth engine. By combining highly trained virtual representatives with an agile SWAT team that can be deployed as needs arise, you create a seamless coverage model. When an in-person rep leaves or steps away, leaders can quickly calibrate the right mix of resources for that territory-ensuring continuity without disruption.

Because virtual teams can cover larger geographies without the downtime of windshield time, they are incredibly efficient at plugging localized gaps. They ensure that HCPs still get the information they need, exactly when they need it, protecting the brand's revenue stream while the organization takes the necessary time to hire and train the perfect in-person replacement.

PE: For pharma executives reading this who realize their "fully staffed" teams might be underperforming, what is the first step they should take to fix it?
Pinto: The very first thing any leader in pharma with responsibility for field teams needs to do is redefine your success metrics. Stop asking, “Are all our seats filled?” and start asking, “What percentage of our territories have maintained consistent, high-quality HCP engagement over the last 90 days?” You must audit your true field productivity, factoring in ramp-up times, recent turnover, and territory coverage gaps.

Once you identify where the invisible leaks are, you need to build flexibility into your commercial model. Look at your deployment strategy and ask yourself if it can handle a 12% vacancy rate without a dip in national sales. If the answer is no, it’s time to look at agile, hybrid deployment solutions that guarantee continuous coverage regardless of your internal headcount fluctuations.

The right partner can make a world of difference in helping pharma leaders navigate this increasingly complex market. Yes, technology like AI is making the lives of these reps more efficient, but nothing replaces the relationship with HCPs. Because ultimately, they're the ones that need to understand the drug, so they can provide what’s best for their patients. Strong sales teams are their most important wingman to make sure they are prepared to deliver at every patient visit.